XML 67 R54.htm IDEA: XBRL DOCUMENT
v3.21.2

Guide Acquisition - Additional Information (Details) - USD ($) $ in Thousands |  | 1 Months Ended | 3 Months Ended | 6 Months Ended |
--- | --- | --- | --- | --- | ---
Feb. 23, 2021 | Feb. 28, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Mar. 31, 2020 | Jun. 30, 2021 | Dec. 31, 2020
Business Acquisition [Line Items] |  |  |  |  |  |  |
Value of shares issued for upfront payment of acquisition |  |  |  | $ 120,032 |  |  |
Research and development expense |  |  |  |  |  | $ 154,953 |
Issuance of common stock from initial public offering/private placement/At-the-Market offering, net of issuance costs |  |  | $ 157,785 | 252,005 | $ 188,323 |  |
Business combination liability for milestones at fair value |  |  | 37,559 |  |  | 37,559 | $ 0
Common Stock |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Value of shares issued for upfront payment of acquisition |  |  |  | 10 |  |  |
Issuance of common stock from initial public offering/private placement/At-the-Market offering, net of issuance costs |  |  | 18 | $ 28 | $ 122 |  |
Guide Therapeutics, Inc. | Merger Agreement |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Business Acquisition, merger agreement date | Feb. 23, 2021 |  |  |  |  |  |
Business combination upfront consideration paid in common stock | $ 120,000 | $ 120,000 |  |  |  |  |
Value of shares issued for upfront payment of acquisition | 120,000 |  |  |  |  |  |
Research and development expense | 155,000 |  |  |  |  |  |
Business combination liability for milestones at fair value | $ 36,500 |  | $ 37,600 |  |  | $ 37,600 |
Guide Therapeutics, Inc. | Merger Agreement | Common Stock |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Number of shares issued for upfront payment of acquisition. | 1,087,153 |  |  |  |  |  |
Guide Therapeutics, Inc. | Merger Agreement | Technology Milestones | Maximum | Former Stockholders and Optionholders |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Potential milestone payable in form of common stock | $ 100,000 |  |  |  |  |  |
Guide Therapeutics, Inc. | Merger Agreement | Product Milestones | Maximum | Former Stockholders and Optionholders |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Potential milestone payable in form of common stock | $ 220,000 |  |  |  |  |  |

X
- Definition The aggregate amount of consideration paid to former stockholders and optionholders in common stock, as part of a business combination, excluding purchase price adjustments. + References No definition available. + Details
Name: | beam_BusinessCombinationUpfrontConsiderationPaidInCommonStock
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares issued for upfront payment of acquisition. + References No definition available. + Details
Name: | beam_NumberOfSharesIssuedForUpfrontPaymentOfAcquisition
Namespace Prefix: | beam_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of potential milestones payable in the form of common stock as part of a business combination. + References No definition available. + Details
Name: | beam_PotentialMilestonePayableInFormOfCommonStock
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Date when the business acquisition agreement was executed, in CCYY-MM-DD format. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph b -URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Value of stock issued pursuant to acquisitions during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueAcquisitions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=beam_GuideTherapeuticsIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=beam_MergerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfTechnologyLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=beam_FormerStockholdersAndOptionholdersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=beam_ContingentConsiderationOfProductLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |